[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008033987A3 - Compositions and methods to prevent cancer with cupredoxins - Google Patents

Compositions and methods to prevent cancer with cupredoxins Download PDF

Info

Publication number
WO2008033987A3
WO2008033987A3 PCT/US2007/078371 US2007078371W WO2008033987A3 WO 2008033987 A3 WO2008033987 A3 WO 2008033987A3 US 2007078371 W US2007078371 W US 2007078371W WO 2008033987 A3 WO2008033987 A3 WO 2008033987A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
cupredoxins
tissues
animals
development
Prior art date
Application number
PCT/US2007/078371
Other languages
French (fr)
Other versions
WO2008033987A2 (en
Inventor
Gupta Tapas Das
Ananda Chakrabarty
Original Assignee
Univ Illinois
Gupta Tapas Das
Ananda Chakrabarty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Gupta Tapas Das, Ananda Chakrabarty filed Critical Univ Illinois
Priority to JP2009528468A priority Critical patent/JP2010503409A/en
Priority to MX2009002787A priority patent/MX2009002787A/en
Priority to BRPI0714987-5A priority patent/BRPI0714987A2/en
Priority to AU2007296429A priority patent/AU2007296429A1/en
Priority to EP07842403A priority patent/EP2061498A4/en
Priority to CA002663498A priority patent/CA2663498A1/en
Publication of WO2008033987A2 publication Critical patent/WO2008033987A2/en
Priority to IL197602A priority patent/IL197602A0/en
Priority to NO20091267A priority patent/NO20091267L/en
Publication of WO2008033987A3 publication Critical patent/WO2008033987A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The present invention further relates to compositions that may comprise cupredoxin(s), and/or variants, derivatives or structural equivalents of cupredoxins, that retain the ability to inhibit the development of premalignant lesions in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to prevent the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.
PCT/US2007/078371 2006-09-14 2007-09-13 Compositions and methods to prevent cancer with cupredoxins WO2008033987A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2009528468A JP2010503409A (en) 2006-09-14 2007-09-13 Compositions and methods for preventing cancer with cupredoxins
MX2009002787A MX2009002787A (en) 2006-09-14 2007-09-13 Compositions and methods to prevent cancer with cupredoxins.
BRPI0714987-5A BRPI0714987A2 (en) 2006-09-14 2007-09-13 cupredoxin cancer prevention compositions and methods
AU2007296429A AU2007296429A1 (en) 2006-09-14 2007-09-13 Compositions and methods to prevent cancer with cupredoxins
EP07842403A EP2061498A4 (en) 2006-09-14 2007-09-13 Compositions and methods to prevent cancer with cupredoxins
CA002663498A CA2663498A1 (en) 2006-09-14 2007-09-13 Compositions and methods to prevent cancer with cupredoxins
IL197602A IL197602A0 (en) 2006-09-14 2009-03-15 Compositions and methods to prevent cancer with cupredoxins
NO20091267A NO20091267L (en) 2006-09-14 2009-03-26 Compositions and methods to prevent cancer with cupredoxins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84435806P 2006-09-14 2006-09-14
US60/844,358 2006-09-14

Publications (2)

Publication Number Publication Date
WO2008033987A2 WO2008033987A2 (en) 2008-03-20
WO2008033987A3 true WO2008033987A3 (en) 2009-04-30

Family

ID=39184582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078371 WO2008033987A2 (en) 2006-09-14 2007-09-13 Compositions and methods to prevent cancer with cupredoxins

Country Status (13)

Country Link
EP (1) EP2061498A4 (en)
JP (2) JP2010503409A (en)
KR (1) KR20090059152A (en)
CN (1) CN101595124A (en)
AU (1) AU2007296429A1 (en)
BR (1) BRPI0714987A2 (en)
CA (1) CA2663498A1 (en)
IL (1) IL197602A0 (en)
MX (1) MX2009002787A (en)
NO (1) NO20091267L (en)
RU (1) RU2009113812A (en)
SG (1) SG174784A1 (en)
WO (1) WO2008033987A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
KR20070108128A (en) 2004-10-07 2007-11-08 아난다 차크라바르티 Cupredoxin derived transport agents and methods of use thereof
US9434770B2 (en) 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
US9598470B2 (en) 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
WO2007012004A2 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
WO2008070666A2 (en) * 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cpg rich dna and cupredoxins
JP2010518123A (en) 2007-02-08 2010-05-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Compositions and methods for preventing cancer with cupredoxins
JP7116165B2 (en) * 2017-09-29 2022-08-09 オンクグノスティクス ゲーエムベーハー Neoplasm and cancer risk determination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
CN1506375A (en) * 2002-12-12 2004-06-23 浙江养生堂天然药物研究所有限公司 Azurin as bacterial protein with wide-spectrum antitumor function and its use and medicinal composition
KR20070108128A (en) * 2004-10-07 2007-11-08 아난다 차크라바르티 Cupredoxin derived transport agents and methods of use thereof
CA2608512A1 (en) * 2005-05-20 2007-02-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
JP2009502797A (en) * 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Compositions and methods for controlling angiogenesis with cupredoxins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARVIDSSON ET AL.: "The azurin gene from Pseudomonas aeruginosa cloning and characterization.", EUR. J. BIOCHEM., vol. 179, 1989, pages 195 - 200, XP008107831 *
YAMADA ET AL.: "Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer.", PNAS, vol. 99, no. 22, 2002, pages 14098 - 14103, XP002486971 *

Also Published As

Publication number Publication date
JP2010503409A (en) 2010-02-04
SG174784A1 (en) 2011-10-28
AU2007296429A1 (en) 2008-03-20
NO20091267L (en) 2009-06-04
KR20090059152A (en) 2009-06-10
JP2014050390A (en) 2014-03-20
BRPI0714987A2 (en) 2013-07-30
MX2009002787A (en) 2009-08-27
IL197602A0 (en) 2011-08-01
RU2009113812A (en) 2010-10-20
EP2061498A2 (en) 2009-05-27
CA2663498A1 (en) 2008-03-20
WO2008033987A2 (en) 2008-03-20
CN101595124A (en) 2009-12-02
EP2061498A4 (en) 2009-11-04

Similar Documents

Publication Publication Date Title
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
WO2008036932A3 (en) Compositions and methods comprising boswellia species
WO2007044084A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2006133271A3 (en) Compositions and methods relating to target-specific photodynamic therapy
WO2008137758A3 (en) Amino acid lipids and uses thereof
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2007103490A3 (en) System for the expression of orthogonal translation components in eubacterial host cells
WO2007102149A3 (en) Hydrazido derivatives of hyaluronic acid
MY148496A (en) Dpp iv inhibitor formulations
WO2006020060A3 (en) Iap binding compounds
WO2008064351A3 (en) (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2011008495A3 (en) Arginase formulations and methods
CL2011000867A1 (en) Da, c and ii crystalline forms of (r) -5- [3-chloro-4- (2,3-dihydroxy-propoxy) -benz [z] ylidene] -2- ([z] - propylimino) -3-o - totil-thiazolidin-4-one; pharmaceutical composition; and use in the treatment or prevention of rejection of transplanted organs, autoimmune syndrome, asthma, diabetes, cancer.
WO2008117125A3 (en) Compositions capable of facilitating penetration across a biological barrier
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2009114725A3 (en) Mobilization op hematopoietic stem cells using cdc42 inhibitors
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2009016181A3 (en) Optical imaging agents
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007092496A3 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780041762.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842403

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 575506

Country of ref document: NZ

Ref document number: 2007296429

Country of ref document: AU

Ref document number: 2663498

Country of ref document: CA

Ref document number: 521/MUMNP/2009

Country of ref document: IN

Ref document number: MX/A/2009/002787

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009528468

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007842403

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007296429

Country of ref document: AU

Date of ref document: 20070913

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097007352

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009113812

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0714987

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090313